EPS: As of FY2025 Q2, the actual value is USD -0.28.

Segment Revenue

• The company has not commenced any operations and will not generate operating revenues until after the completion of its initial Business Combination.

Operational Metrics

• For the three months ended June 30, 2025, the company reported a net loss of $893,896, compared to a net loss of $217,185 for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $1,632,451, compared to $592,492 for the same period in 2024.
• Operating expenses for the three months ended June 30, 2025, were $317,427, compared to $469,611 for the same period in 2024.
• Operating expenses for the six months ended June 30, 2025, were $637,683, compared to $1,066,744 for the same period in 2024.

Cash Flow

• Cash used in operating activities for the six months ended June 30, 2025, was $430,447, compared to $1,559,688 for the same period in 2024.
• As of June 30, 2025, the company had $22,170 in cash available to meet working capital needs and a working capital deficit of approximately $7.9 million.

Unique Metrics

• The company has entered into multiple promissory notes with Public Gold Marketing Sdn. Bhd. for working capital, with a total outstanding balance of $4,570,422 as of June 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company is focused on completing a Business Combination by September 9, 2025, or up to December 9, 2025, if extended. The company intends to complete a business combination before the mandatory liquidation date.
• Non-Core Business: The company has entered into a Merger Agreement with Alps Life Sciences Inc, which involves merging with Alps Global Holding Pubco and Alps Biosciences Merger Sub, with the aim of Alps Holdco becoming a wholly-owned subsidiary of PubCo. The company has also engaged in PIPE Investment agreements to raise additional capital for use by PubCo following the closing of the Business Combination.